EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors

Douglas V N P Oliveira, Edyta Biskup iD, Colm J O'Rourke, Julie L Hentze, Jesper B Andersen, Claus Høgdall, Estrid V Høgdall

Molecular Diagnosis & Therapy · 2024

DOI: 10.1007/s40291-024-00740-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diagnosis & Therapy, 2024. Verfasst von Douglas V N P Oliveira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: DNA Methylation, Ovarian Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Købmand Niels Erik Munk Pedersen Fonden, A.P. Møller and wife Chastine Mc-Kinney Møllers Foundation, European Union Marie Curie program – EpiTarget.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Epithelial ovarian cancer (EOC) represents a significant health challenge, with high-grade serous ovarian cancer (HGSOC) being the most common subtype. Early detection is hindered by nonspecific symptoms, leading to late-stage diagnoses and poor survival rates. Biomarkers are crucial for early diagnosis and personalized treatment OBJECTIVE: Our goal was to develop a robust statistical procedure to identify a set of differentially methylated probes (DMPs) that would allow differentiation between HGSOC and benign ovarian tumors. METHODOLOGY: Using the Infinium EPIC Methylation array, we analyzed the methylation profiles of 48 ovarian samples diagnosed with HGSOC, borderline ovarian tumors, or benign ovarian disease. Through a multi-step statistical procedure combining univariate and multivariate logistic regression models, we aimed to identify CpG sites of interest. RESULTS AND CONCLUSIONS: We discovered 21 DMPs and developed a predictive model validated in two independent cohorts. Our model, using a distance-to-centroid approach, accurately distinguished between benign and malignant disease. This model can potentially be used in other types of sample material. Moreover, the strategy of the model development and validation can also be used in other disease contexts for diagnostic purposes. Ovarian cancer presents a major health challenge; due to unspecific symptoms it is often diagnosed at late stages, thus resulting in poor survival rates. Hence the need to identify biomarkers that would enable early and accurate diagnosis, as well as tailored treatment. In our work, we compared methylation profiles of ovarian cancer and non-malignant ovarian tissue samples, and presented a predictive algorithm, accurately distinguishing between benign and malignant ovarian disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationOvarian NeoplasmsCystadenocarcinoma, SerousHumansFemaleMiddle AgedBiomarkers, TumorAgedAdultNeoplasm GradingCpG IslandsDiagnosis, DifferentialCarcinoma, Ovarian Epithelial

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
  • Biotech Research & Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Gynecology, Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark. estrid.hoegdall@regionh.dk.

ORCID-Profile: Edyta Biskup

Förderung

  • Købmand Niels Erik Munk Pedersen Fonden
  • A.P. Møller and wife Chastine Mc-Kinney Møllers Foundation
  • European Union Marie Curie program – EpiTarget
  • Mermaid III foundation
  • Copenhagen University

Zitieren

APA

Oliveira, D. V. N. P., Biskup, E., O'Rourke, C. J., Hentze, J. L., Andersen, J. B., Høgdall, C., & Høgdall, E. V. (2024). Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors. Molecular Diagnosis & Therapy. https://doi.org/10.1007/s40291-024-00740-y

Vancouver

Oliveira DVNP, Biskup E, O'Rourke CJ, Hentze JL, Andersen JB, Høgdall C, et al. Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors. Molecular Diagnosis & Therapy. 2024. doi:10.1007/s40291-024-00740-y

BibTeX
@article{Oliveira2024,
  author = {Oliveira, Douglas V N P and Biskup, Edyta and O'Rourke, Colm J and Hentze, Julie L and Andersen, Jesper B and Høgdall, Claus and Høgdall, Estrid V},
  title = {Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors},
  journal = {Molecular Diagnosis & Therapy},
  year = {2024},
  doi = {10.1007/s40291-024-00740-y}
}
Kostenlos starten →